Genetic Technologies Acquires Perlegen Assets | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has acquired certain assets from Perlegen Sciences, which ceased operations late last year.

Australia's Genetic Technologies said that the primary asset it has obtained is Perlegen's BrevaGen breast cancer risk test. In addition, it said that it acquired a suite of granted patents valid to 2022 that augment and extend its current non-coding patent portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.